May 5, 2025 04:07 PM EDTUpdated May 6, 08:55 AM

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy

Zachary Brennan

Senior Editor

Capricor Therapeutics’ cell therapy for Duchenne muscular dystrophy will face an FDA advisory committee ahead of an approval decision that’s expected Aug. 31, the company …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy

Zachary Brennan

Senior Editor

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Another Bristol Myers exec goes to Acadia; David Southwell takes CEO job at ARCH-backed cancer biotech

Sanofi, Regeneron report underwhelming COPD data for IL-33 antibody, shares drop

As a challenging first half nears a close, biopharma uncertainty persists

From weeks to days: how Aizon Intelligent Agents transform pharma validation

FDA ad­comm will re­view Capri­cor's cell ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA adcomm will review Capricor's cell therapy for Duchenne muscular dystrophy